Your browser is no longer supported. Please, upgrade your browser.
Settings
BGNE BeiGene, Ltd. daily Stock Chart
BGNE [NASD]
BeiGene, Ltd.
Index- P/E- EPS (ttm)-1.31 Insider Own28.70% Shs Outstand45.60M Perf Week-2.48%
Market Cap4.27B Forward P/E- EPS next Y-6.61 Insider Trans-4.36% Shs Float8.62M Perf Month16.37%
Income-31.40M PEG- EPS next Q-1.76 Inst Own56.60% Short Float19.35% Perf Quarter13.08%
Sales220.20M P/S19.38 EPS this Y-111.90% Inst Trans22.24% Short Ratio4.82 Perf Half Y115.92%
Book/sh17.81 P/B5.26 EPS next Y-257.30% ROA-5.40% Target Price101.33 Perf Year214.41%
Cash/sh16.61 P/C5.64 EPS next 5Y- ROE-7.50% 52W Range27.89 - 118.95 Perf YTD208.30%
Dividend- P/FCF- EPS past 5Y- ROI-31.60% 52W High-18.29% Beta-
Dividend %- Quick Ratio9.30 Sales past 5Y- Gross Margin99.10% 52W Low248.48% ATR4.53
Employees321 Current Ratio9.30 Sales Q/Q- Oper. Margin-14.50% RSI (14)62.41 Volatility4.86% 5.46%
OptionableYes Debt/Eq0.21 EPS Q/Q335.80% Profit Margin-14.20% Rel Volume0.69 Prev Close93.60
ShortableYes LT Debt/Eq0.20 EarningsNov 09 Payout- Avg Volume345.83K Price97.19
Recom1.90 SMA208.81% SMA508.82% SMA20051.42% Volume208,489 Change3.84%
Nov-14-17Downgrade Robert W. Baird Outperform → Neutral $58 → $83
Sep-28-17Reiterated Maxim Group Buy $77 → $120
Aug-07-17Initiated Ladenburg Thalmann Buy $81
Jul-06-17Reiterated Maxim Group Buy $57 → $73
Jul-05-17Reiterated Maxim Group Buy $52 → $57
Sep-22-16Initiated Maxim Group Buy $41
Feb-29-16Initiated Robert W. Baird Outperform $44
Feb-29-16Initiated Morgan Stanley Overweight
Feb-29-16Initiated Goldman Buy $33
Dec-18-17 06:00AM  BeiGene Initiates Pivotal Trial of PARP inhibitor Pamiparib (BGB-290) in China in Patients with Ovarian Cancer GlobeNewswire
Dec-11-17 10:24AM  Celgene's Lymphoma Strategy Is Its Biggest Positive, Analyst Says Benzinga
10:00AM  BeiGene Presents Initial Phase 1b Data for BTK Inhibitor Zanubrutinib (BGB-3111) Combined with PD-1 Antibody Tislelizumab (BGB-A317) at the 59th American Society of Hematology Annual Meeting GlobeNewswire
Dec-09-17 12:15PM  BeiGene Presents Preliminary Phase 1b Data on BTK Inhibitor Zanubrutinib (BGB-3111) in Non-Hodgkins Lymphoma at the 59th American Society of Hematology Annual Meeting GlobeNewswire
09:00AM  BeiGene Presents Updated Preliminary Phase 1b Data on BTK Inhibitor Zanubrutinib (BGB-3111) Combined with GAZYVA® (Obinutuzumab) at the 59th American Society of Hematology Annual Meeting GlobeNewswire
Dec-08-17 07:15PM  Beigene Ltd (BGNE) CEO John Oyler Sold $13.5 million of Shares GuruFocus.com
Dec-04-17 04:05PM  BeiGene to Webcast an Analyst and Investor Event from the American Society of Hematology Annual Meeting GlobeNewswire +16.67%
Nov-29-17 07:15PM  Beigene Ltd (BGNE) CEO John Oyler Sold $7.3 million of Shares GuruFocus.com
Nov-13-17 04:05PM  BeiGene Reports Third Quarter 2017 Financial Results GlobeNewswire
04:05PM  BeiGene Expands Global Pivotal Program for BTK Inhibitor BGB-3111 GlobeNewswire
Nov-01-17 09:00AM  BeiGene Announces Oral Presentation and Posters at the 59th American Society of Hematology Annual Meeting GlobeNewswire
Oct-19-17 02:03AM  China biotech's 'coming out party' masks long road ahead Reuters
Sep-29-17 05:50AM  [$$] Celgene Invests in Acceleron, BeiGene Barrons.com +6.19%
Sep-28-17 09:00AM  BeiGene Presents Preliminary Phase 1 Data for BGB-A317 in Chinese Patients with Advanced Tumors at the 20th Annual Meeting of CSCO GlobeNewswire
Sep-21-17 04:15PM  BeiGene Announces Presentation at the 20th Annual Meeting of the Chinese Society of Clinical Oncology GlobeNewswire
Sep-19-17 07:31AM  These 3 Biotech Stocks Just Hit 52-Week Highs: Are They Buys? Motley Fool
Sep-12-17 01:34PM  [$$] Celgene Launch to Lift BeiGene Barrons.com
Sep-11-17 03:00AM  BeiGene Presents Preliminary Phase 1 Data for BGB-A317 in Multiple Solid Tumors at the ESMO 2017 Congress GlobeNewswire
Sep-08-17 06:00AM  BeiGene Presents Preliminary Phase 1/2 Clinical Data on PARP Inhibitor BGB-290 in Patients with Advanced Solid Tumors at the European Society for Medical Oncology 2017 Congress GlobeNewswire
Aug-31-17 04:05PM  BeiGene Announces Closing of Global Strategic Oncology Collaboration with Celgene Corporation GlobeNewswire
Aug-30-17 06:05PM  BeiGene Announces Presentations at the European Society for Medical Oncology 2017 Congress GlobeNewswire
04:15PM  BeiGene to Present at Upcoming Investor Conferences GlobeNewswire
Aug-10-17 10:14PM  BeiGene Announces Pricing of $175 Million Public Offering GlobeNewswire -6.03%
Aug-09-17 04:11PM  BeiGene Announces Proposed Public Offering GlobeNewswire
04:01PM  BeiGene Reports Second Quarter 2017 Financial Results GlobeNewswire
02:36PM  How Celgene Performed in 2Q17 Market Realist
08:01AM  Why BeiGene Soared 56.6% In July Motley Fool
Jul-17-17 06:06AM  These 3 Stocks Have Doubled Investors' Money in 2017 Motley Fool
Jul-12-17 09:39AM  Biotech Stock Roundup: Arena Shoots Up on Study Data, CELG Inks Immuno-Oncology Deal Zacks
Jul-10-17 11:32AM  [$$] BeiGene Boosted by Celgene Deal Barrons.com
Jul-07-17 04:42PM  Why Celgene's $413 Million Gamble Helps This Small Biotech More Investor's Business Daily +5.88%
Jul-06-17 04:52PM  Celgene (CELG), BeiGene Team Up For PD-1 Inhibitor in China Zacks +26.80%
04:42PM  Celgene Enters PD1 Market with BeiGene Deal TheStreet.com
04:28PM  Why HSN, Herman Miller, and BeiGene Jumped Today Motley Fool
02:07PM  Here's Why BeiGene Ltd. Rose as Much as 31.4% on Thursday Motley Fool
12:21PM  Celgene signs deal with BeiGene for tumor cancer treatment Reuters
09:29AM  Biotech Movers: Immuno-Oncology Pact With Celgene Sends BeiGene Shares Soaring TheStreet.com
08:35AM  How Transformative Is This Licensing Deal for BeiGene? 24/7 Wall St.
08:27AM  BeiGene stock surges 12% on Celgene cancer collaboration MarketWatch
07:30AM  US STOCKS-Futures lower ahead of trade, ADP jobs data Reuters
Jul-05-17 10:05PM  Celgene to buy BeiGene stake, to develop tumor cancer treatment Reuters
09:15PM  BeiGene to Host Investor Conference Call on Global Strategic Collaboration with Celgene GlobeNewswire
09:00PM  Celgene Corporation Enters Into Global Strategic Immuno-Oncology Collaboration with BeiGene to Advance PD-1 Inhibitor Program for Solid Tumor Cancers Business Wire
10:37AM  This Biotech Stock Is Surging More Than 20% Today TheStreet.com
08:33AM  BeiGene (BGNE) Surges: Stock Moves 20.8% Higher Zacks
07:00AM  BeiGene Initiates Pivotal Trial of PD-1 Antibody BGB-A317 in China in Patients with Urothelial Cancer GlobeNewswire
Jun-29-17 05:10AM  BeiGene Presents Preliminary Phase 1 Data on BGB-A317 in Patients with Hepatocellular Carcinoma at the ESMO 19th World Congress on Gastrointestinal Cancer GlobeNewswire
Jun-16-17 05:50AM  BeiGene Presents Initial Phase 1 Data on BTK Inhibitor BGB-3111 Combined with Obinutuzumab at the 14th International Conference on Malignant Lymphoma and Announces Additional Planned Global Registrational Trials for BGB-3111 GlobeNewswire +5.22%
Jun-15-17 10:00AM  BeiGene Presents Updated Phase 1 Data on BTK Inhibitor BGB-3111 in Patients with Waldenströms Macroglobulinemia at the 14th International Conference on Malignant Lymphoma GlobeNewswire
Jun-14-17 06:00AM  BeiGene Presents Updated Phase 1 Data on BTK Inhibitor BGB-3111 in Patients with Chronic Lymphocytic Leukemia and Small Lymphocytic Lymphoma at the 14th International Conference on Malignant Lymphoma GlobeNewswire
Jun-07-17 04:15PM  BeiGene to Present at Upcoming Investor Conferences GlobeNewswire
12:00PM  BeiGene to Present Data on BGB-3111 at the 14th International Conference on Malignant Lymphoma and to Host Conference Call GlobeNewswire
Jun-05-17 09:00AM  BeiGene Presents Initial Phase 1 Data on Anti-PD-1 Antibody BGB-A317 Combined with PARP Inhibitor BGB-290 at the 2017 American Society for Clinical Oncology Annual Meeting GlobeNewswire
May-17-17 04:15PM  BeiGene to Present at the 2017 UBS Global Healthcare Conference GlobeNewswire
May-10-17 04:15PM  BeiGene Reports First Quarter 2017 Financial Results GlobeNewswire
Apr-26-17 03:08PM  ETFs with exposure to BeiGene Ltd. : April 26, 2017 Capital Cube
Apr-21-17 07:00AM  BeiGene Announces Presentation on a Phase I Study of PD-1 Antibody BGB-A317 in Combination with PARP Inhibitor BGB-290 at the 2017 American Society of Clinical Oncology Annual Meeting GlobeNewswire
07:00AM  BeiGene Announces Initiation of First Pivotal Study in China of PD-1 Antibody BGB-A317 GlobeNewswire
Apr-03-17 09:26AM  BEIGENE, LTD. Files SEC form 8-K, Other Events, Financial Statements and Exhibits
Apr-02-17 01:16PM  BeiGene Presents Phase IB Data on RAF Dimer Inhibitor BGB-283 at the 2017 American Association for Cancer Research Annual Meeting GlobeNewswire
Mar-31-17 08:15AM  Blog Coverage Agenus Announced Restructuring of Business Accesswire
Mar-28-17 01:04PM  BEIGENE, LTD. Financials
Mar-24-17 10:16AM  BeiGene Ltd. :BGNE-US: Earnings Analysis: 2016 By the Numbers : March 24, 2017 Capital Cube
10:16AM  BeiGene Ltd. :BGNE-US: Earnings Analysis: 2016 By the Numbers : March 24, 2017
Mar-22-17 04:32PM  BEIGENE, LTD. Files SEC form 8-K, Results of Operations and Financial Condition, Financial Statements and Exhibits
04:15PM  BeiGene Reports Fourth Quarter and Full Year 2016 Financial Results GlobeNewswire
Mar-09-17 04:22PM  BEIGENE, LTD. Files SEC form 8-K, Other Events, Financial Statements and Exhibits
04:15PM  BeiGene Announces Initiation of Pivotal Study in China with BTK Inhibitor BGB-3111 in Patients with Relapsed or Refractory CLL/SLL GlobeNewswire
Mar-07-17 07:21AM  BEIGENE, LTD. Files SEC form 8-K, Entry into a Material Definitive Agreement, Creation of a Direct Financial Obligati
07:00AM  BeiGene and Guangzhou Development District Establish Joint Venture to Build Biologics Manufacturing Facility GlobeNewswire
Mar-02-17 09:00AM  BeiGene Announces Presentation of Phase IB Data on BGB-283 at the 2017 American Association for Cancer Research Annual Meeting GlobeNewswire
09:00AM  BeiGene Announces Initiation of First Pivotal Study in China with BTK Inhibitor BGB-3111 GlobeNewswire
Feb-27-17 04:15PM  BeiGene to Present at the Cowen and Company 37th Annual Health Care Conference GlobeNewswire
Feb-08-17 04:15PM  BeiGene to Participate in the LEERINK Partners 6th Annual Global Healthcare Conference GlobeNewswire
Jan-26-17 11:11AM  Beigene Ltd (ADR) (BGNE): Heres Our Take at Insider Monkey
Jan-25-17 10:07AM  BEIGENE, LTD. Files SEC form 8-K, Other Events, Financial Statements and Exhibits +8.24%
08:00AM  BeiGene Initiates Global Phase III Trial of the BTK Inhibitor BGB-3111 in Waldenströms Macroglobulinemia GlobeNewswire
Dec-30-16 09:00AM  BeiGene Announces First Patient Dosing in China Phase I Trial with Investigational Anti-PD-1 Monoclonal Antibody BGB-A317 GlobeNewswire
Dec-21-16 04:15PM  BeiGene Announces First Patient Dosing in China with Investigational PARP Inhibitor BGB-290 GlobeNewswire
Dec-16-16 07:53AM  Do Hedge Funds Love Nobilis Health Corp (USA) (HLTH)? at Insider Monkey
Dec-14-16 07:16AM  Should You Add Hawaiian Telcom HoldCo Inc (HCOM) to Your Portfolio? at Insider Monkey
06:12AM  Is Federated National Holding Co (FNHC) A Good Stock To Buy? at Insider Monkey
Dec-12-16 09:09AM  BeiGene (BGNE): Strong Industry, Solid Earnings Estimate Revisions +5.18%
Dec-09-16 01:06PM  Should You Buy Beigene Ltd (ADR) (BGNE)? at Insider Monkey
Dec-07-16 07:54AM  Cancer Genetics, Inc. Is Selected by BeiGene, Ltd. to Collaborate on Clinical Trial Services & Advance Portfolio of Novel Oncology Therapeutics GlobeNewswire
Dec-06-16 06:04AM  BEIGENE, LTD. Files SEC form 8-K, Other Events, Financial Statements and Exhibits
Dec-05-16 10:00PM  BeiGene Presents Updated Clinical Data on BTK Inhibitor BGB-3111 in Patients with Waldenströms Macroglobulinemia at the 2016 American Society of Hematology Annual Meeting GlobeNewswire -8.26%
11:15AM  BeiGene Presents Updated Clinical Data on BTK Inhibitor BGB-3111 in Patients with Chronic Lymphocytic Leukemia and Small Lymphocytic Leukemia at the 2016 American Society of Hematology Annual Meeting GlobeNewswire
Dec-01-16 06:11AM  [$$] Three Biotechs With Bullish Insider Buying at Barrons.com
Nov-23-16 04:25PM  BeiGene Announces Closing of $200 Million Public Offering GlobeNewswire
02:15PM  5 Stocks Insiders Love Right Now
Nov-17-16 07:27PM  BeiGene Announces Pricing of $200 Million Public Offering GlobeNewswire -11.38%
10:40AM  BeiGene Prices Secondary Offering
06:26AM  BEIGENE, LTD. Files SEC form 8-K, Other Events, Financial Statements and Exhibits
Nov-16-16 05:59PM  BeiGene Announces Proposed Public Offering GlobeNewswire
Nov-14-16 06:17AM  BEIGENE, LTD. Files SEC form 8-K, Other Events, Financial Statements and Exhibits +8.85%
Nov-11-16 07:00AM  BeiGene Presents Updated Clinical Data on PD-1 Antibody BGB-A317 in Patients with Advanced Solid Tumors at the Society for Immunotherapy of Cancer 31st Annual Meeting GlobeNewswire -10.36%
06:26AM  BeiGene reports 3Q loss
Nov-10-16 11:15AM  Beigene Files for Secondary Offering +6.27%
08:59AM  BEIGENE, LTD. Files SEC form 8-K, Results of Operations and Financial Condition, Financial Statements and Exhibits
Chinese biotech developing cancer therapies for China and global markets.
Insider Trading Relationship Date Transaction Cost #Shares Value ($) #Shares Total SEC Form 4
Huang JaneCMO, HematologyDec 13Option Exercise29.511,50044,2651,500Dec 15 04:05 PM
Huang JaneCMO, HematologyDec 13Sale94.251,500141,3810Dec 15 04:05 PM
OYLER JOHNChief Executive OfficerDec 08Sale95.5752,8175,047,758119,137Dec 08 05:57 PM
OYLER JOHNChief Executive OfficerDec 07Sale93.4059,7375,579,304171,954Dec 08 05:57 PM
OYLER JOHNChief Executive OfficerDec 06Sale92.2931,4462,902,224231,691Dec 08 05:57 PM
Huang JaneCMO, HematologyDec 04Sale86.001,10094,6000Dec 05 09:15 AM
OYLER JOHNChief Executive OfficerNov 29Sale82.9236,3403,013,458263,137Nov 29 05:33 PM
OYLER JOHNChief Executive OfficerNov 28Sale85.5232,9852,820,864299,477Nov 29 05:33 PM
OYLER JOHNChief Executive OfficerNov 27Sale86.7616,5811,438,582332,462Nov 29 05:33 PM
Huang JaneCMO, HematologyNov 20Sale87.001,00087,0001,100Nov 20 05:14 PM
Huang JaneCMO, HematologyNov 16Sale85.0060051,0002,100Nov 20 05:14 PM
OYLER JOHNChief Executive OfficerNov 15Sale80.2366,0685,300,508349,043Nov 15 08:12 PM
OYLER JOHNChief Executive OfficerNov 14Sale79.7459,8354,770,950415,111Nov 15 08:12 PM
Peterson Amy C.CMO, Immuno-oncologyNov 13Sale82.963,601298,7470Nov 15 08:11 PM
OYLER JOHNChief Executive OfficerNov 13Sale83.0625,0542,080,916474,946Nov 15 08:12 PM
BAKER BROS. ADVISORS LPDirectorAug 11Buy71.00176,05612,499,9763,476,256Aug 14 03:49 PM
Wang XiaodongDirectorJul 12Sale72.4420,0001,448,7040Jul 13 06:31 PM
Glazer Donald W.DirectorJul 10Sale72.1510,810779,9000Jul 12 09:37 PM
OYLER JOHNChief Executive OfficerJul 06Sale64.82219,40014,221,1250Jul 10 06:44 PM
Wang XiaodongDirectorJun 28Sale44.9535,0001,573,34520,000Jun 30 04:36 PM
OYLER JOHNChief Executive OfficerJun 23Sale44.2839,8951,766,35346,840Jun 26 08:38 PM
OYLER JOHNChief Executive OfficerJun 22Sale44.0858,6052,583,26986,735Jun 26 08:38 PM
Wang XiaodongDirectorJun 02Sale40.005,539221,56055,000Jun 06 04:20 PM
Wang XiaodongDirectorMay 04Sale41.014,491184,17160,539May 05 05:50 PM
Wang XiaodongDirectorMay 03Sale40.719,970405,87165,030May 05 05:50 PM
OYLER JOHNChief Executive OfficerMay 01Sale42.022,10088,243145,340May 01 07:44 PM
OYLER JOHNChief Executive OfficerApr 27Sale40.3734,0491,374,565147,440May 01 07:44 PM
Wang XiaodongDirectorApr 05Sale36.8311,650429,08575,000Apr 07 05:10 PM
Wang XiaodongDirectorMar 24Sale36.6018,787687,63486,650Mar 24 06:57 PM
Wang XiaodongDirectorMar 23Sale37.0011,041408,462105,437Mar 24 06:57 PM
Wang XiaodongDirectorMar 22Sale37.758,279312,517116,478Mar 24 06:57 PM
OYLER JOHNChief Executive OfficerMar 20Sale40.0213,234529,611181,489Mar 20 07:06 PM
OYLER JOHNChief Executive OfficerMar 17Sale40.022,717108,737194,723Mar 20 07:06 PM
OYLER JOHNChief Executive OfficerMar 16Sale38.7716,038621,725197,440Mar 20 07:06 PM
Wang XiaodongDirectorMar 10Sale39.947,304291,702124,757Mar 10 07:16 PM
Wang XiaodongDirectorMar 09Sale39.9518,596742,843132,061Mar 10 07:16 PM
Wang XiaodongDirectorMar 08Sale39.7810,992437,211150,657Mar 10 07:16 PM
OYLER JOHNChief Executive OfficerMar 06Sale40.2319,816797,258213,478Mar 06 07:00 PM
OYLER JOHNChief Executive OfficerMar 03Sale40.8340,0911,636,968233,294Mar 06 07:00 PM
OYLER JOHNChief Executive OfficerMar 02Sale41.2549,0922,025,104273,385Mar 06 07:00 PM
Wang XiaodongDirectorFeb 27Sale38.104,444169,328161,649Feb 27 09:11 PM
Wang XiaodongDirectorFeb 24Sale38.1428,4021,083,114166,093Feb 27 09:11 PM
Wang XiaodongDirectorFeb 23Sale38.575,505212,351194,495Feb 27 09:11 PM
OYLER JOHNChief Executive OfficerFeb 21Sale39.9810,359414,162322,477Feb 21 07:23 PM
OYLER JOHNChief Executive OfficerFeb 17Sale40.677,204292,981332,836Feb 21 07:23 PM
OYLER JOHNChief Executive OfficerFeb 16Sale40.6547,4001,926,867340,040Feb 21 07:23 PM